Compare Mesoblast Limited (MESO) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Zscaler Inc — how do they compare? Mesoblast Limited trades at $14.32 (market cap $1.75B), while Zscaler Inc trades at $229.79 (market cap $35.35B). The key difference: Zscaler Inc is far larger — about 20.2× Mesoblast Limited's market cap, and Zscaler Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Zscaler Inc for 41 Days on average.
| MESO | ZS | |
|---|---|---|
Market Cap | $1.75B | $35.35B |
Volume | 239,027 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $20.96 | $336.27 |
52-Week Low | $13.19 | $118.05 |
Typical Hold Time | 14 Days | 41 Days |
Enterprise Value | $1.83B | $33.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Zscaler (ZS) trades at $230.23, up 7.81% in the last 24 hours, with a bullish technical signal from moving averages. The company reported strong revenue growth, reaching $2.67 billion in 2025, and has beaten EPS estimates for three consecutive quarters. However, it remains unprofitable with a net income margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day on October 6, 2026.
The outlook is mixed: robust revenue growth and AI-driven bookings offer upside, but profitability concerns and high valuation multiples pose risks. Analyst consensus is bullish with a $222.83 price target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in cybersecurity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
